You are here
Efficacy and Safety for Primary Care Physicians
for Primary Care Physicians
In this course you will learn about basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy, and how the efficacy and safety of this approach surpasses that of the individual components. The course will provide information on how to identify patients who are most likely to benefit from this combination. Practical considerations will be discussed, including tips on how to best manage patients during treatment with basal insulin–GLP-1 receptor agonist combination therapy.
Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk